Overview of Treatment Strategies and Response Status Before HDC in 52 Children With Relapsed B-NHL
| Chemotherapy Before Relapse . | Response Status Before HDC for Relapse . | Type of Second-Line Relapse Treatment . | Type of Third-Line Treatment . | Local Irradiation . | Surgery . |
|---|---|---|---|---|---|
| COPAD | 5 CR2 | COPADM, MTX-Ara-C | — | 1 | 1 |
| 6 SR | COPADM, MIME, VP16-CDDP | — | 3 | 1 | |
| 7 RR | COPADM, VP16-CDDP | CYM | 1 | — | |
| LMB 81/84 | 8 CR2 | COPADM, VP16-CDDP | — | 1 | 3 |
| 3 SR | COPADM, MTX-Ara-C, VP16-CDDP | — | — | — | |
| 2 RR | VP16-CDDP | — | — | 1 | |
| LMB 86/90 | 2 CR2 | VP16-CDDP | — | 1 | — |
| 3 SR | CYVE, VP16-CDDP | — | — | 1 | |
| 1 RR | CYVE, VP16-CDDP | MIME | — | — | |
| Other | 6 CR2 | LMB86 + CYVE | — | 1 | 3 |
| 1 SR | VP16-CDDP | — | 1 | 1 | |
| 4 RR | CYVE, VP16-CDDP | — | — | 1 | |
| 4 relapse | VP16-CDDP | — | 1 | 1 |
| Chemotherapy Before Relapse . | Response Status Before HDC for Relapse . | Type of Second-Line Relapse Treatment . | Type of Third-Line Treatment . | Local Irradiation . | Surgery . |
|---|---|---|---|---|---|
| COPAD | 5 CR2 | COPADM, MTX-Ara-C | — | 1 | 1 |
| 6 SR | COPADM, MIME, VP16-CDDP | — | 3 | 1 | |
| 7 RR | COPADM, VP16-CDDP | CYM | 1 | — | |
| LMB 81/84 | 8 CR2 | COPADM, VP16-CDDP | — | 1 | 3 |
| 3 SR | COPADM, MTX-Ara-C, VP16-CDDP | — | — | — | |
| 2 RR | VP16-CDDP | — | — | 1 | |
| LMB 86/90 | 2 CR2 | VP16-CDDP | — | 1 | — |
| 3 SR | CYVE, VP16-CDDP | — | — | 1 | |
| 1 RR | CYVE, VP16-CDDP | MIME | — | — | |
| Other | 6 CR2 | LMB86 + CYVE | — | 1 | 3 |
| 1 SR | VP16-CDDP | — | 1 | 1 | |
| 4 RR | CYVE, VP16-CDDP | — | — | 1 | |
| 4 relapse | VP16-CDDP | — | 1 | 1 |
Abbreviations: COPAD protocol, cyclophosphamide, vincristine, prednisone, and doxorubicin; COPADM, cyclophosphamide, vincristine, prednisone, doxorubicin, and MTX; LMB81 protocol, consecutive cycles of the COPAD combination plus high-dose MTX (3 g/m2) and intrathecal injections of MTX and Ara-C; LMB84 protocol, consecutive cycles of the COPAD combination plus high-dose MTX (3 g/m2) and continuous intravenous Ara-C infusion (500 mg/m2) plus intrathecal injections of MTX and Ara-C; LMB 86/89 (high-risk arm) protocol, high-dose MTX (12 g/m2), intrathecal triple therapy, and consolidation with high-dose Ara-C, VP16, and cranial irradiation; CYVE, high-dose Ara-C and VP16; MIME, methylgag, ifosfamide, MTX, and VP16; CYM, MTX and Ara-C.